Last reviewed · How we verify

NCT04125784

Lipid Profile and Diabetes Mellitus in People With HIV

Completed Last updated 31 March 2023
What this trial tests

trial in HIV Infections in 450 participants. Completed in 28 February 2023.

Timeline
1 August 2021
Primary endpoint
30 December 2022
28 February 2023

Quick facts

Lead sponsorMoritz Oberndorfer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment450
Start date1 August 2021
Primary completion30 December 2022
Estimated completion28 February 2023
Sites1 location across Austria

Conditions studied

Sponsor

Moritz Oberndorfer

Who can join

18 and older, any sex, with HIV Infections or Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Traditional risk factors for cardiovascular diseases have been shown to have an even higher impact in the HIV infected population. The original study from 2014 was a cross sectional study into the prevalence of cardiovascular risk factors (namely, dyslipidaemia and diabetes mellitus) in people living with HIV (PLWHIV) in Austria. The aim of this follow up study is to see the progression of our study sample and to see what prevalence levels may be found after 7 years. This epidemiological evaluation is conceptualized to document real life major cardiovascular risk factors of HIV-infected patients, focusing on lipid profiles and diabetes mellitus risk and to compare with the baseline values from the original study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing